Jump to content

User:Kevin Gorman/hyq

From Wikipedia, the free encyclopedia
Kevin Gorman/hyq
Clinical data
AHFS/Drugs.comConsumer Drug Information
Routes of
administration
Subcutaneous

Sources

[edit]

Yeah, I really do just list my sources first while developing an article

  • Long-Term Efficacy and Safety of Recombinant Human Hyaluronidase (rHuPH20)- Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (HyQvia; IGHy) in Patients with Primary Immunodeficiencies (PI) [1]
  • Tolerability and Pharmacokinetic Properties of Ondansetron Administered Subcutaneously With Recombinant Human Hyaluronidase in Minipigs and Healthy Volunteers - it involves minipigs! [2]
  • Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency[3]
  • Pharmaceutical Approval Update [4]
  • Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration (antibody info) [5]
  • Human Immunoglobulin 10 % with Recombinant Human Hyaluronidase: Replacement Therapy in Patients with Primary Immunodeficiency Disorders (this one requires EBSCO) [6]
  1. ^ Wasserman, Richard L.; Stein, Mark R.; Melamed, Isaac; Kobrynski, Lisa J.; Gupta, Sudhir; Puck, Jennifer M.; Rubinstein, Arye; Engl, Werner; McCoy, Barbara; Leibl, Heinz; Yel, Leman (February 2015). "Long-Term Efficacy and Safety of Recombinant Human Hyaluronidase (rHuPH20)- Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (HyQvia; IGHy) in Patients with Primary Immunodeficiencies (PI)". Journal of Allergy and Clinical Immunology. 135 (2): AB96. doi:10.1016/j.jaci.2014.12.1247. {{cite journal}}: |access-date= requires |url= (help)
  2. ^ Dychter, Samuel S.; Harrigan, Rena; Bahn, Jesse D.; Printz, Marie A.; Sugarman, Barry J.; DeNoia, Emanuel; Haughey, David B.; Fellows, Daniel; Maneval, Daniel C. (February 2014). "Tolerability and Pharmacokinetic Properties of Ondansetron Administered Subcutaneously With Recombinant Human Hyaluronidase in Minipigs and Healthy Volunteers". Clinical Therapeutics. 36 (2): 211–224. doi:10.1016/j.clinthera.2013.12.013.
  3. ^ Wasserman, Richard L.; Melamed, Isaac; Stein, Mark R.; Gupta, Sudhir; Puck, Jennifer; Engl, Werner; Leibl, Heinz; McCoy, Barbara; Empson, Victoria G.; Gelmont, David; Schiff, Richard I. (October 2012). "Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency". Journal of Allergy and Clinical Immunology. 130 (4): 951–957.e11. doi:10.1016/j.jaci.2012.06.021. {{cite journal}}: |access-date= requires |url= (help)
  4. ^ Gohil K (2014). "Pharmaceutical approval update". P T. 39 (11): 746–72. PMC 4218669. PMID 25395816.
  5. ^ Rosengren, Sanna; Dychter, Samuel S.; Printz, Marie A.; Huang, Lei; Schiff, Richard I.; Schwarz, Hans-Peter; McVey, John K.; Drake, Fred H.; Maneval, Dan C.; Kennard, Don A.; Frost, Gregory I.; Sugarman, Barry J.; Muchmore, Douglas B. (13 May 2015). "Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration". The AAPS Journal. 17 (5): 1144–1156. doi:10.1208/s12248-015-9782-0. {{cite journal}}: |access-date= requires |url= (help)
  6. ^ Sanford, Mark (13 June 2014). "Human Immunoglobulin 10 % with Recombinant Human Hyaluronidase: Replacement Therapy in Patients with Primary Immunodeficiency Disorders". BioDrugs. 28 (4): 411–420. doi:10.1007/s40259-014-0104-3. {{cite journal}}: |access-date= requires |url= (help); no-break space character in |title= at position 24 (help)


Medical use

[edit]

Inflammation

[edit]

Other uses

[edit]

Dosage

[edit]

Adverse effects

[edit]

Contraindications

[edit]

Skin

[edit]

Other adverse effects

[edit]

Interactions

[edit]

Chemical properties

[edit]

Mechanism of action

[edit]

Additional mechanisms

[edit]

Pharmacokinetics

[edit]

History

[edit]

References

[edit]

<references/